In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients

Digestive and Liver Disease

Volumn 40, Issue 9, 2008, Pages 731-736

  Tanaka, T ^a   Okanobu, H ^a   Yoshimi, S ^a   Murakami, E ^a   Kogame, A ^a   Imagawa, H ^a   Numata, Y ^a   Kuga, Y ^a   Moriya, T ^a   Ohya, T ^a   Kajiyama, G ^a  

^a CHUGOKU ROSAI HOSPITAL   (Japan)

Author keywords

Adacolumn; Deep colonic ulcers; GMA; Inflammatory bowel disease; Loss of mucosal tissue; Mucosal neutrophils; Steroid na ve patients; Steroid dependent; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE;

ADSORPTION; ADULT; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; COLON ULCER; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; DIZZINESS; DRUG EXPOSURE; FEMALE; FLUSHING; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKAPHERESIS; MALE; MONOCYTE; NEUTROPHIL; REMISSION; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; BIOPSY, NEEDLE; COHORT STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; LEUKAPHERESIS; MALE; MIDDLE AGED; MONOCYTES; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STEROIDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 48149087447     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.02.012     Document Type: Article

References (37)

1. Shimoyama T., Sawada K., Hiwatashi N., Sawada T., Suzuki Y., Saniabadi A.R., et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16 (2001) 1-9
2. Saniabadi A.R., Hanai H., Takeuchi K., Sawada K., Bjarnason I., Lofberg R., et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7 (2003) 48-59
3. Hanai H., Watanabe F., Takeuchi K., Yamada M., Saniabadi A., Bjarnason I., et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol 1 (2003) 28-35
4. Kashiwagi N., Sugimura K., Koiwai H., Saniabadi A., Adachi M., and Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 6 (2002) 1334-1341
5. Suzuki Y., Yoshimura N., Saniabadi A.R., and Saito Y. Selective granulocytes and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49 (2004) 565-571
6. Saniabadi A.R., Hanai H., Suzuki Y., Sawada K., Bjarnason I., Lofberg R., et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?. J Clin Apher 20 (2005) 171-184
7. Kanke K., Nakano M., and Hiraishi H. Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis 36 (2004) 512-518
8. Naganuma M., Funakoshi S., Sakuraba A., Takagi H., Inoue N., Ogata H., et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 10 (2004) 251-257
9. Yamamoto T., Umegae S., and Kitagawa T. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20 (2004) 783-792
10. Domenech E., Hinojosa J., Esteve-Comas M., Gassull A., and Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 20 (2004) 1347-1352
11. Suzuki Y., Yoshimora N., Saito Y., and Saniabadi A. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 51 (2006) 2031-2038
12. McCarthy D.A., Rampton D.S., and Liu Y.-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86 (1991) 489-493
13. Rugtveit J., Brandtzaeg P., Halstensen T.S., Fausa O., and Scott H. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 35 (1994) 669-674
14. Meuret G., Bitzi A., and Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 74 (1978) 501-503
15. Brannigan A.E., O'Connell P.R., and Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 13 (2000) 361-366
16. Cassatella M.A. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16 (1995) 21-26
17. Nikolaus S., Bauditz J., and Gionchetti P. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 42 (1998) 470-476
18. Mahida Y.R. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6 (2000) 21-33
19. Hanauer S.B. Inflammatory bowel disease: Epidemiology, Pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12 (2006) S3-S9
20. In: Allison M.C., Dhillon A.P., Lewis W.G., and Pounder R.E. (Eds). Inflammatory Bowel Disease (1998), Mosby, London 15-95
21. Tibble J.A., Sigthorsson G., Bridger D., Fagerhol M.K., and Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119 (2000) 15-22
22. Limburg P., David M., Ahlquist A., and Sandborn W.J. Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am J Gastroenterol 95 (2000) 2831-2837
23. Hanai H., Watanabe F., Yamada M., Sato Y., Iida T., Tozawa K., et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid dependent moderately severe ulcerative colitis. Digestion 70 (2004) 36-44
24. Rachmilewitz D., and on behalf of an international study group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 298 (1989) 82-86
25. Gironella M., Iovanna J.L., Sans M., Gil F., Penalva M., Penalva M., et al. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut 54 (2005) 1244-1253
26. Caprilli R., and D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 39 (2007) 435-437
27. Takemoto K., Kato J., Kuriyama M., Nawa T., Kurome M., Okada H., et al. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis 39 (2007) 422-429
28. Panés J., Guilera M., Ginard D., Hinojosa J., González-Carro P., González-Lara V., et al. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective?. Dig Liver Dis 39 (2007) 617-625
29. Bresci G., Parisi G., Mazzoni A., Scatena F., and Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis 39 (2007) 430-434
30. Yamamoto T., Saniabadi A.R., Maruyama Y., Umegae S., and Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 39 (2007) 626-633
31. Meagher L.C., Cousin J.M., Seckl J.R., and Haslett C. Opposing effects of glucocorticoids on the rate of appoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156 (1996) 4422-4428
32. Saniabadi A.R., Hanai H., Fukunaga K., Sawada K., Bjarnason I., Lofberg R., et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transf Apher Sci 37 (2007) 191-200
33. ++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008, in press.
34. Aoki H., Nakamura K., Yoshimatsu Y., Tsuda Y., Irie M., Fukuda K., et al. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8 and the expression of toll like receptor 2 on granulocytes. Dig Dis Sci 52 (2007) 1427-1433
35. Lerebours E., Bussel A., Modigliani R., Bastit D., Florent C., and Rabian C. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Gastroenterology 107 (1994) 357-361
36. Kanai K., and Watanabe M. Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel diseases. Expert Opin Biol Ther 5 (2005) 451-462
37. Heimann T.M., and Aufses Jr. A.H. The role of peripheral lymphocytes in the prediction of recurrence in Crohn's disease. Surg Gynecol Obstet 160 (1985) 295-298